http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강혁재 ( Hyuk Jae Kang ),정민형 ( Min Hyung Jung ),김종준 ( Jong June Kim ),김대연 ( Dae Yeon Kim ),김종혁 ( Jong Hyeok Kim ),서대식 ( Dai Shik Seo ),김용만 ( Yong Man Kim ),김영탁 ( Young Tak Kim ),남주현 ( Joo Hyun Nam ),목정은 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.12
Objective: To review the clinicopathological characteristics and prognosis of patients with malignant mixed Mullerian tumor (MMMT) of the uterus. Methods: Retrospective clinical study was done on 26 patients diagnosed with the MMMT of the uterus at our hospital from Janurary, 1994 to December, 2004. Demographic data, pathologic findings, stages, treatment, prognosis and survival time were reviewed. Results: The median age of patients was 59 years. Most of the patients (76.9%) were in the postmenopausal state. The most common symptom was vaginal bleeding (65.4%). There were 17 patients (65.4%) with stage I, 3 patients (11.6%) with stage II, 4 patients (15.4%) with stage III, 2 patients (7.6%) with stage IV disease in this study. Of the hysterectomy specimens, 4 (15.4%) of them were heterologous tumors, 22 (84.6%) of them were homologous tumors. Overall 5 year survival rate of all stages was 60% and the patients with advanced stages (III, IV) showed poorer prognosis than the patients with early stages (I, II) (P=0.001). Myometrial invasion depth was also significant prognostic factor (P<0.001). Conclusion: The MMMT of the uterus is a highly malignant tumor and the significant prognostic factor is the FIGO stage and myometrial invasion depth.
자궁내막증 환자의 정상위치 자궁내막 및 이소성 자궁내막에서의 EGF의 전령리보핵산 및 단백질의 발현
강혁재 ( Hyuk Jae Kang ),김정훈 ( Chung Hoon Kim ),이영진 ( Young Jin Lee ),김성훈 ( Sung Hoon Kim ),채희동 ( Hee Dong Chae ),강병문 ( Byung Moon Kang ) 대한산부인과학회 2009 Obstetrics & Gynecology Science Vol.52 No.2
Objective: This study was performed to investigate the expression of EGF mRNA and protein in eutopic and ectopic endometrial tissues of the patients with endometriosis and in eutopic endometrial tissues of the patients without endometriosis. Methods: Study group was composed of 34 women with endometriosis taking surgical treatment at the Department of Obstetrics and Gynecology, Asan Medical Center, from October 2004 to December 2005. Control group consisted of 14 women who had undergone surgical treatment for cervical intraepithelial neoplasia or benign gynecologic conditions other than endometriosis during the same period. Eutopic endometrial tissues of both groups and ectopic endometrial tissues of study group were collected during the operations. Real time reverse transcriptase-polymerase chain reaction (RT-PCR) was used to quantify EGF mRNA of these tissues. Western blot analysis was performed to ascertain the expression of EGF protein. Results: The expressions of EGF mRNA were significantly lower in both eutopic (P<0.01) and ectopic (P<0.01) endometrial tissues of the women with endometriosis than in eutopic endometrial tissues of control group. The expressions of EGF protein were shown to be lower in both eutopic and ectopic endometrial tissues of the women with endometriosis than in eutopic endometrial tissues of control group. Conclusion: We found some correlations between the lower expression of EGF in endometrial tissues and the development of endometriosis. In addition, the change or defect of some factors in the eutopic endometrium might play an important role in the development of endometriosis.
김정훈,강혁재,김소라,전균호,이향아,김성훈,채희동,강병문,Kim, Chung-Hoon,Kang, Hyuk-Jae,Kim, So-Ra,Jeon, Gyun-Ho,Lee, Hyang-Ah,Kim, Sung-Hoon,Chae, Hee-Dong,Kang, Byung-Moon The Korean Society for Reproductive Medicine 2010 Clinical and Experimental Reproductive Medicine Vol.37 No.2
목 적: 과배란유도하 자궁강내 인공수정시술을 받는 불임 환자들을 대상으로 연성자극요법의 효과를 성선자극호르몬분비호르몬 길항제 다회투여법과 비교, 평가하고자 본 연구가 시행되었다. 연구방법: 불임 환자 80명을 연성자극요법군 (n=40)과 성선자극호르몬분비호르몬 길항제 다회투여법군 (n=40)으로 무작위로 1:1로 배정하였다. 두 군 모두에서 질식초음파상 평균 직경이 18 mm에 도달한 난포가 1개, 또는 17 mm에 도달한 난포가 2개 이상 관찰될 때, 재조합 사람융모성성선자극호르몬 250 ${\mu}g$을 1회 투여했으며, 이 후 36~40시간째에 자궁강내 인공수정이 시행되었다. 결 과: 과배란유도를 위해 사용된 재조합 사람난포자극호르몬의 총용량과 투여일수는 연성자극요법군에서 유의하게 적었다 (p<0.001, p<0.001). 두 군 모두에서 조기 황체화호르몬 급상승은 관찰되지 않았다. 시술 주기당 임상적 임신율, 자연유산율, 다태임신율, 중증 난소과자극증후군의 발생빈도는 두 군간에 차이를 보이지 않았다. 결 론: 연성자극요법은 성선자극호르몬분비호르몬 길항제 다회투여법에 비하여 재조합 사람난포자극호르몬을 적은 용량, 짧은 기간 사용하면서도 유사한 임신율을 나타내므로, 과배란유도하 자궁강내 인공수정을 시행 받는 환자를 위한 환자 친화적이고 효과적인 과배란유도법이 될 수 있을 것이다. Objective: To evaluate the effectiveness of soft stimulation protocol using GnRH antagonist/clomiphene citrate (CC)/recombinant FSH (rFSH) in patients undergoing controlled ovarian stimulation (COS) with intrauterine insemination (IUI), compared with GnRH antagonist multiple dose protocol (MDP) using GnRH antagonist/rFSH. Methods: Eighty infertile women were randomized to soft stimulation protocol group (n=40) or GnRH antagonist MDP group (n=40). In both groups, IUI was performed 36~40 hours after hCG injection. Statistical analysis was performed using Student's t-test, $\chi^2$ test or Fisher's exact test as appropriate. Results: Total dose and days of rFSH required for COS were significantly fewer in soft stimulation protocol group (p<0.001, p<0.001). A premature LH surge did not occur in any patients of both groups. Clinical pregnancy rate per cycle was similar between the two groups. Conclusion: Soft stimulation protocol provides comparable pregnancy rates to GnRH antagonist MDP despite fewer total dose and days of rFSH, and so can become one of the patient-friendly, cost-effective alternatives for infertile patients undergoing COS with IUI.
다낭성난소증후군 환자의 체외수정시술에서 Rosiglitazone이 난소기질혈류와 난소반응 및 체외수정결과에 미치는 영향
이사라 ( Sa Ra Lee ),김정훈 ( Chung Hoon Kim ),강혁재 ( Hyuk Jae Kang ),김진희 ( Jin Hee Kim ),홍석호 ( Seok Ho Hong ),김성훈 ( Sung Hoon Kim ),채희동 ( Hee Dong Chae ),강병문 ( Byung Moon Kang ) 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.6
Objective: We investigated to evaluate the effects of rosiglitazone on intraovarian stromal blood flow, ovarian response to stimulation, and in vitro fertilization-embryo transfer (IVF-ET) outcome in polycystic ovary syndrome (PCOS) patients. Methods: Forty-six infertile women, 24 to 36 years of age, with only tubal factor and PCOS, were randomized into either rosiglitazone (n=23) or placebo (n=23) treatment group. A rosiglitazone of 4 ㎎ once daily was started on day 1 of the cycle prior to gonadotropin releasing hormone (GnRH) agonist suppression, and continued to the day of human chorionic gonadotropin (hCG) injection in study group. For a control Group, placebo was administered during the same period. Each of the 2 groups consisted of 23 cycles of IVF-ET. Transvaginal color Doppler analyses (resistance index (RI) and pulsatility index (PI)) were performed to assess the intraovarian stromal blood flow in all participants on the starting days of rosiglitazone or placebo (RI0, PI0), GnRH agonist administration (RI1, PI1) and ovarian stimulation (RI2, PI2). Results: There were no significant differences in age, body mass index (BMI), infertiliy duration, endocrine profile, fasting and 2-hour glucose levels after a 75 gm glucose load, RI0 and PI0 values of ovarian stromal artery between two groups. RI1 and PI1 values were higher in study group, but the differences were not statistically significant. RI2 and PI2 values in study group were significantly higher than in control group (0.60±0.04 versus 0.56±0.03; P<0.05, 0.99±0.14 versus 0.88±0.05; P<0.05, respectively). The number of follicles both 10-14㎜ and ≥14㎜ in diameter on the day of hCG injection and the number of retrieved oocytes were significantly lower in study group. The number of retrieved oocytes was significantly higher in study group. The clinical pregnancy rate was higher in study group but it did not make statistical significance. Conclusions: Rosiglitazone therapy could reduce the intraovarian stromal blood flow and appeared to be beneficial in improving response to ovulation induction and IVF outcomes in PCOS patients.